ANGPTL4 Inhibition in Adults with Elevated Triglyceride Levels
Authors' conclusion
Inhibition of ANGPTL4 with MAR001 significantly reduced fasting triglyceride levels at 12 weeks. (Funded by Marea Therapeutics; TYDAL-TIMI 78 ClinicalTrials.gov number, NCT07028749.).
Study context
- Population
- Adults with a nonfasting triglyceride level of at least 175 mg per deciliter and remnant cholesterol of at least 35 mg per deciliter at initial screening, then fasting triglyceride of at least 150 mg per deciliter and remnant cholesterol of at least 30 mg per deciliter on confirmatory screeningenrolled, 235 received at least one dose and were included in the primary efficacy analyses · 177 (MAR001) · 59 (placebo)
- Participants
- 236 adults
- Comparison
- MAR001 at a dose of 300, 450, or 900 mg vs matching placebo
- Placebon = 59
- Primary endpoint
- Percent change from baseline in the fasting triglyceride level (placebo-adjusted change)
- Follow-up
- Week 12
Methodological detailspart A reported
- Part A reported
Primary result
As reported in the abstract
Percent change from baseline in the fasting triglyceride level (placebo-adjusted change)
Placebo-adjusted least-squares mean percent change
−39.1 percentage points
P < 0.001
MAR001 300 mg vs placebo
Placebo-adjusted least-squares mean percent change
−40.5 percentage points
P < 0.001
MAR001 450 mg vs placebo
Placebo-adjusted least-squares mean percent change
−45.3 percentage points
P < 0.001
MAR001 900 mg vs placebo
Further findings
Baseline characteristics
- Mean age
- 60.4 years
- Women
- 39%
- Median triglyceride level
- 249.5 mg per deciliter (interquartile range, 210.0 to 313.0)
Safety
- Adverse events — placebo
- 78%
- Adverse events: pooled MAR001 69%
Original publication
ANGPTL4 Inhibition in Adults with Elevated Triglyceride Levels. N Engl J Med. Published 9 November 2026. doi:10. 1056/ nejmoa2612463
Composed by AI from the published abstract and checked against it. How Briefs are made →